Premenstrual Syndrome Treatment Market By Treatment 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Premenstrual Syndrome Treatment Market
Premenstrual Syndrome Treatment Market: By Treatment (Painkillers, Oral Contraceptive Pills, Estrogen-Only Patches & Implants, Gonadotropin-Releasing Hormone (GnRH) Analogues, Selective Serotonin Reuptake Inhibitors (SSRIs)) & By Region - Forecast (2016-2021)
Report Code : HCR 0267
Updated Date: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Premenstrual syndrome (PMS) is medical condition involving emotional, physical, psychological, and mood disturbances that occur after a woman's ovulation, and typically ends with the onset of her menstrual flow. The most common mood-related symptoms involved in premenstrual syndrome are irritability, depression, crying, oversensitivity, and mood swings. The most common physical symptoms involved in premenstrual syndrome are fatigue, bloating, breast tenderness (mastalgia), acne, and appetite changes with food cravings. One of the advanced and more severe form of PMS is premenstrual dysphoric disorder (PMDD) also known as late luteal phase dysphoric disorder, occurs in a smaller number of women and leads to significant loss of function because of unusually severe symptoms. Globally increasing registered cases of PMS due to life style related issues and increasing awareness amongst women in the developed nations is expected to drive the demand for PMS however regulations over the usage of such medicines in some of the nations and higher R&D cost involved to develop new drugs and treatments is expected to be the key constraints market during the period of study.

This report identifies the global premenstrual syndrome treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to premenstrual syndrome treatment market.
Premenstrual Syndrome Treatment Market

Geographically, North America dominated the premenstrual syndrome treatment market due to higher awareness about such diseases, higher registered cases due to life style related health issues and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest consumer of premenstrual syndrome treatment. Asia Pacific is projected to have the fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.

This report segments premenstrual syndrome treatment market on the basis of treatment type and regional market as follows:

  • On the basis of treatment type this report on premenstrual syndrome treatment market is segmented as follows, covering major segments as follows: Painkillers, Oral contraceptive pills, Estrogen-only patches and implants, Gonadotropin-releasing hormone (GnRH) analogues, Selective serotonin reuptake inhibitors (SSRIs)
  • This report on premenstrual syndrome treatment has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the premenstrual syndrome treatment market. Some of the major companies’ profiles in detail are as follows:
  • Pherin Pharmaceuticals, Inc.
  • DEKK-TEC, Inc.
  • Umecrine Mood AB
  • MetP Pharma AG
  • Bristol Meyer Squibb
1. Premenstrual Syndrome Treatment Market –Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Premenstrual Syndrome Treatment Market– Forces
   4.1. Drivers
      4.1.1. Growing registered cases of PMS due to changing life style
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Premenstrual Syndrome Treatment Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life cycle Analysis
   5.5. Suppliers & Distributors
6. Premenstrual Syndrome Treatment Market, By Treatment
   6.1. Painkillers
   6.2. Oral contraceptive pills
   6.3. Estrogen-only patches & implants
   6.4. Gonadotropin-releasing hormone (GnRH) analogues
   6.5. Selective serotonin reuptake inhibitors (SSRIs)
7. Premenstrual Syndrome Treatment Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Premenstrual Syndrome Treatment – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Pherin Pharmaceuticals, Inc.
   9.2. DEKK-TEC, Inc.
   9.3. Umecrine Mood AB
   9.4. MetP Pharma AG
   9.5. Bristol Meyer Squibb
   9.6. Merck and Co.
   9.7. Novartis AG
   9.8. Pfizer, Inc.
   9.9. Cipla Laboratories.
   9.10. Dr. Reddy’s Laboratories Ltd
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibiliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports